Disclosed herein are spiro-oxindole compounds of formula (I), (IV), (V), (VIII), (IX), (XI), (XII) and (XIII) wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful in treating sodium channel-mediated diseases or conditions such as pain, depression, cardiovascular diseases, respiratory diseases, and psychiatric diseases. Particularly preferred compounds include: 1-[(2R)-tetrahydrofuran-2-ylmethyl]-4H-spiro[furo[3,2-g][1,3]benzodioxine-6,3-indol]-2(1H)-one 1-[(2R)-tetrahydrofuran-2-ylmethyl]-6,7-dihydro-5H-spiro[furo[3,2-g]chromene-3,3-indol]-2(1H)-one 2,3-dihydrospiro[furo[3,2-f][1,4]benzodioxine-9,3-indol]-2(1H)-one 3,4-dihydro-2H-spiro[furo[2,3-h][1,5]benzodioxepine-9,3-indol]-2(1H)-one 1-methylspiro[furo[3,2-f][1,3]benzoxazole-7,3-indole]-2,2(1H,1H)-dione 3-methyl-1-{ [5-(trifluoromethyl)furan-2-yl]methyl} spiro[furo[2,3-f][1,3]benzoxazole-7,3-indole]-2,2(1H,3H)-dione 1-(pyridin-2-ylmethyl)-7,8-dihydro-6H-spiro-[furo[2,3-g]chromene-3,3-indol]-2(1H)-one 1-{ [3-(trifluoromethyl)pyridin-2-yl]methyl} -7,8-dihyrdospiro[1,4-dioxino[2,3-g][1,3]benzodioxine-4,3-indol]-2(1H)-one.
